RAINBOW BABIES & CHILDRENS HOSPITA
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $34.4M
- Transactions
- 4,480
- Companies
- 40
- Average per transaction
- $7,688
Who reported the payments
| Pfizer | $14,324,372 |
| Seagen Inc. | $2,411,827 |
| Novartis | $2,094,157 |
| Genentech, Inc. | $2,037,319 |
| AbbVie | $1,929,334 |
| E.r. Squibb & Sons, L.L.C. | $1,548,466 |
| Regeneron | $1,530,032 |
| Exelixis Inc. | $1,468,748 |
| Amgen | $980,584 |
| Incyte Corporation | $694,570 |
| Bristol Myers Squibb | $582,194 |
| Merck | $289,198 |
| CSL Behring | $282,901 |
| Stemline Therapeutics Inc. | $232,268 |
| Radius Health, Inc. | $229,484 |
| Bayer | $229,197 |
| Roche Products Limited | $227,645 |
| Dermavant Sciences, Inc. | $218,239 |
| Glaukos Corporation | $210,288 |
| F. Hoffmann-la Roche AG | $188,858 |
| Medtronic | $165,105 |
| Bausch Health US, LLC | $116,882 |
| Orthopediatrics Corp. | $116,662 |
| AVEO Pharmaceuticals, Inc. | $116,585 |
| Insmed, Inc. | $114,086 |
| Shockwave Medical, Inc | $109,402 |
| Trillium Therapeutics USA, LLC | $103,722 |
| Y-mabs Therapeutics, Inc. | $97,661 |
| Hill-rom Holdings, Inc | $95,538 |
| Gilead | $84,455 |
| Intercept Pharmaceuticals, Inc. | $78,067 |
| Insulet Corporation | $76,290 |
| Springworks Therapeutics, Inc. | $75,664 |
| Philips North America LLC | $68,584 |
| Astellas Pharma Global Development | $64,084 |
| Dexcom, Inc. | $63,155 |
| Ascendis Pharma Endocrinology Inc | $62,412 |
| Global Blood Therapeutics, Inc. | $61,316 |
| Biomarin Pharmaceutical Inc. | $60,965 |
| Tetraphase Pharmaceuticals, Inc. | $59,121 |